Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).

@article{Philip2014DualBO,
  title={Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).},
  author={Philip Agop Philip and Bryan H. Goldman and Ramesh K. Ramanathan and H. P. Lenz and Andrew M. Lowy and Robert P. Whitehead and Takeru Wakatsuki and Syma Iqbal and Rakesh Gaur and Jacqueline Benedetti and Charles David Blanke},
  journal={Cancer},
  year={2014},
  volume={120 19},
  pages={2980-5}
}
BACKGROUND Targeting a single pathway in pancreatic adenocarcinoma (PC) is unlikely to affect its natural history. We tested the hypothesis that simulataneous targeting of the epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) pathways would significantly improve progression-free survival (PFS) by abrogating reciprocal signaling that promote drug resistance METHODS This was a phase Ib/II study testing cixutumumab, combined with erlotinib and gemcitabine… CONTINUE READING
Highly Cited
This paper has 157 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS
21 Citations
40 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

157 Citations

050100'13'15'17
Citations per Year
Semantic Scholar estimates that this publication has 157 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 40 references

Similar Papers

Loading similar papers…